98%
921
2 minutes
20
The widespread occurrence of amyloidosis in many neurodegenerative diseases, including Alzheimer's, highlights the urgent need for early detection methods. Traditional approaches often fall short in sensitivity, specificity, and the ability to operate within complex biological matrices. Fluorescence spectroscopy, which leverages the unique properties of extrinsic fluorescence sensors, has emerged as a promising avenue for amyloid detection. Thioflavin-T (ThT), while extensively utilized, faces several disadvantages such as poor blood-brain barrier penetration, short emission wavelength, and lack of sensitivity to oligomeric protein aggregates. These limitations necessitate the development of improved amyloid probes with enhanced properties for the better detection and understanding of neurodegenerative diseases. In this context, YOPRO-1, a cyanine-based molecular rotor probe, has been identified as a potent amyloid fibril sensor characterized by its turn-on fluorescence response and specificity for amyloid fibrils over native protein forms. Utilizing a variety of spectroscopic techniques, including steady-state emission, ground-state absorption, time-resolved fluorescence, and molecular docking, we demonstrate the superior selectivity and sensitivity of YOPRO-1 for amyloid fibrils. The probe exhibits a remarkable 245-fold increase in fluorescence intensity upon binding to insulin fibrils, which is a common amyloid model. This capability facilitates its application in complex biological matrices, such as high-percentage human serum, which has rarely been demonstrated by previous amyloid sensing probes. Furthermore, the commercial availability of YOPRO-1 avoids the challenges associated with the synthesis of specific probes, thereby marking a significant advancement in amyloid detection methodologies. Our findings highlight the potential of YOPRO-1 as a versatile and effective tool for the early diagnosis of amyloid-related diseases, offering a foundation for future therapeutic and diagnostic applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1021/acsabm.5c00186 | DOI Listing |
Ann Clin Transl Neurol
September 2025
Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy.
Background: Plasma p-tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p-tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).
Methods: We consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay.
Ann Neurol
September 2025
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Objective: The objective of this study was to determine the predictive value of amyloid-positron emission tomography (PET) versus the plasma ratio of phosphorylated tau at threonine 217 (p-tau217) to non-phosphorylated tau217 (%p-tau217) for tau-PET transitions (T- to T+). The added value of combining plasma amyloid-β 42 and amyloid-β 40 (Aβ42/40) and %p-tau217 into an amyloid probability score (APS2) was also assessed.
Methods: Mayo Clinic Study of Aging (MCSA) participants had plasma markers measured at via mass spectrometry (MS), an amyloid-PET scan, and a tau-PET (meta-temporal region of interest [ROI]) negative scan (standardized uptake value ratio [SUVR] <1.
J Histotechnol
September 2025
Department of Pathology, Peking University Third Hospital, Beijing, China.
Amyloidosis encompasses a spectrum of rare disorders characterized by extracellular amyloid deposition. Achieving an accurate early diagnosis of systemic amyloidosis necessitates biopsy-specific pathological evaluation. Formalin-fixed, paraffin-embedded liver biopsy specimens were examined using Congo red staining, electron microscopy, immunohistochemistry (IHC), immunofluorescence, and Congo red-assisted laser microdissection with mass spectrometry (LMD/MS).
View Article and Find Full Text PDFAlzheimers Dement
September 2025
Department of Neurology, Beijing TianTan Hospital, Capital Medical University, Beijing, China.
Cognitive impairment and dementia, including Alzheimer's disease (AD), pose a global health crisis, necessitating non-invasive biomarkers for early detection. This review highlights the retina, an accessible extension of the central nervous system (CNS), as a window to cerebral pathology through structural, functional, and molecular alterations. By synthesizing interdisciplinary evidence, we identify retinal biomarkers as promising tools for early diagnosis and risk stratification.
View Article and Find Full Text PDFAlzheimers Dement
September 2025
Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, South Korea.
Introduction: We developed and validated age-related amyloid beta (Aβ) positron emission tomography (PET) trajectories using a statistical model in cognitively unimpaired (CU) individuals.
Methods: We analyzed 849 CU Korean and 521 CU non-Hispanic White (NHW) participants after propensity score matching. Aβ PET trajectories were modeled using the generalized additive model for location, scale, and shape (GAMLSS) based on baseline data and validated with longitudinal data.